Clinical Trial

A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019)

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Researchers are studying MK-8527, a new medicine for preventing HIV-1 (human immunodeficiency virus type 1) infection and want to learn if MK-8527 can be given together with rifampin. Rifampin is commonly used to treat people with latent tuberculosis infection (LTBI). The main goal of this study is to learn what happens to MK-8527 in the body over time when given with and without the medication rifampin in participants with LTBI.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-15.
Trial Details
NCT Number NCT07600775
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Enrollment 14 participants
Start Date 2026-09-01
Primary Completion 2027-01-19 (estimated)
Study Completion 2027-01-19 (estimated)
Updated on ClinicalTrials.gov 2026-08-03